{
  "eval_id": "S46",
  "eval_file": "evals/single/S46.json",
  "timestamp": "2025-09-18T16:55:10.846158Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with HR-positive, HER2-negative unresectable or metastatic breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. The main on-label consideration is its use after progression on these treatments. Please send the EMA SmPC by email if you need the exact wording or figures."
}